Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Large Increase in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 98,600 shares, a growth of 104.5% from the September 15th total of 48,204 shares. Based on an average daily trading volume, of 611,232 shares, the short-interest ratio is presently 0.2 days. Currently, 0.6% of the company’s stock are sold short.

Enlivex Therapeutics Trading Up 4.0%

Shares of NASDAQ ENLV opened at $0.22 on Friday. The company has a 50-day moving average price of $0.99 and a 200-day moving average price of $6.59. Enlivex Therapeutics has a 1 year low of $0.21 and a 1 year high of $27.15.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ENLV shares. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. Zacks Research lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $247.50.

Institutional Trading of Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENLV. WINTON GROUP Ltd purchased a new position in shares of Enlivex Therapeutics during the second quarter valued at approximately $55,000. Bank of America Corp DE raised its position in Enlivex Therapeutics by 53.2% in the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after buying an additional 45,303 shares during the last quarter. Finally, Susquehanna International Group LLP lifted its stake in Enlivex Therapeutics by 1,428.5% during the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after acquiring an additional 147,334 shares in the last quarter. 1.02% of the stock is owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.